Consun Pharmaceutical Group Limited (01681) published a Next Day Disclosure Return dated 28 October 2025. According to the document, the total issued ordinary share capital did not change during the reporting period, remaining at 847,973,407 shares as of 28 October 2025.

The filing shows that between 14 October 2025 and 28 October 2025, the company repurchased an aggregate of 2,370,000 shares for cancellation but not yet cancelled. These repurchases occurred at prices ranging from approximately HKD14.91 to HKD15.76 per share. On 28 October 2025 specifically, 159,000 shares were repurchased on the Hong Kong Stock Exchange at a highest and lowest price of HKD15.43 and HKD15.26, respectively, with an aggregate consideration of HKD2,449,720.

The company disclosed that its existing repurchase mandate authorizes the repurchase of up to 85,126,334 shares, of which 7,565,000 shares (about 8.8868% of the total issued shares at the date of the resolution) have been repurchased on the Exchange to date. The filing indicates a moratorium period until 27 November 2025 if any new share issue or sale of treasury shares is considered following the share repurchases. The announcement confirms that all repurchases complied with relevant listing rules and other regulatory requirements.